Virologica Sinica

, Volume 33, Issue 5, pp 453–455 | Cite as

Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus

  • Jiaming Lan
  • Yao Deng
  • Jingdong Song
  • Baoying Huang
  • Wenling Wang
  • Wenjie Tan

Dear Editor,

Middle East respiratory syndrome coronavirus (MERS-CoV), first isolated in 2012, has emerged zoonotically among humans (van Boheemen et al.2012). Since then, MERS-CoV continues to be a public health concern, with a fatality rate of 35%. On-going MERS-CoV outbreaks highlight the urgent need for the development of interventional measures, including an effective vaccine against MERS-CoV infection. Currently, no licensed therapeutic or vaccine is available (Okba et al.2017).

MERS-CoV spike (S) protein mediates coronaviral penetration into host cells via initial interaction with the host cell surface receptor. Based on the major immunodominant region of S protein, vaccines against MERS-CoV infection have been developed using purified coronaviral S protein and DNA or viral vector-based vaccines expressing full-length MERS-CoV S protein or part of the S protein (Okba et al.2017). However, efforts are required to achieve optimal protective responses, such as a higher titer of...



This work was supported by the Megaproject for Infectious Disease Research of China (2016ZX10004001-003 and 2014ZX10004001-002 to W.T.), and the National Key Research and Development Program of China (2016YFD0500300 to W.T., 2016YFC1200901 to Y.D., and 2016YFC1200200 to B.H). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Compliance with Ethics Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Animal and Human Rights Statement

Animal studies were conducted in strict accordance with the Guide for the Care and Use of Laboratory Animals of the People’s Republic of China. The study protocol was approved by the Committee on the Ethics of Animal Experiments of the Chinese Centre for Disease Control and Prevention.


  1. Deng Y, Lan J, Bao L, Huang B, Ye F, Chen Y, Yao Y, Wang W, Qin C, Tan W (2018) Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect 7:60CrossRefGoogle Scholar
  2. Lan J, Deng Y, Chen H, Lu G, Wang W, Guo X, Lu Z, Gao GF, Tan W (2014) Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS ONE 9:e112602CrossRefGoogle Scholar
  3. Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G (2011) Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 29:6606–6613CrossRefGoogle Scholar
  4. Okba NM, Raj VS, Haagmans BL (2017) Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. Curr Opin Virol 23:49–58CrossRefGoogle Scholar
  5. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3:e00473–12Google Scholar
  6. Wang C, Zhang X, Gai W, Zhao Y, Wang H, Wang H, Feng N, Chi H, Qiu B, Li N, Wang T, Gao Y, Yang S, Xia X (2017) MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget 8:12686–12694PubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.MOH Key Laboratory of Medical Virology, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and PreventionBeijingChina
  2. 2.Department of Pathogenic BiologyHebei Medical UniversityShijiazhuangChina

Personalised recommendations